Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer

@inproceedings{Kawasaki2015ClinicopathologicalSO,
  title={Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer},
  author={Yota Kawasaki and Sumiya Ishigami and Takaaki Arigami and Yoshikazu Uenosono and Shigehiro Yanagita and Yasuto Uchikado and Yoshiaki Kita and Yuka Nishizono and Hiroshi Okumura and Akihiro Nakajo and Yuko Kijima and Kosei Maemura and Shoji Natsugoe},
  booktitle={BMC Cancer},
  year={2015}
}
BackgroundThe transcription factor nuclear factor (erythroid-2)–related factor 2 (Nrf2) was originally identified as a critical regulator of intracellular anti-oxidants and of phase II detoxification enzymes through its transcriptional up-regulation of many anti-oxidant response element (ARE)-containing genes. Nrf2 protects not only normal cells but also cancer cells from cellular stress, and enhances cancer cell survival. Some studies have shown that Nrf2 expression in cancer patients has… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Expression of Keap1 and Nrf2 in diffuse large B-cell lymphoma and its clinical significance

  • Experimental and therapeutic medicine
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer.

  • Asian Pacific journal of cancer prevention : APJCP
  • 2013
VIEW 1 EXCERPT

Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 1 EXCERPT